A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are widely recommended for initial HIV-1 treatment. Bictegravir (BIC, B) is a novel, once-daily INSTI with potent antiviral activity being developed in coformulation with emtricitabine and tenofovir alafenamide (F/TAF). METHODS: In this Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630742/
http://dx.doi.org/10.1093/ofid/ofx163.1076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630742/
http://dx.doi.org/10.1093/ofid/ofx163.1076

Ejemplares similares